AUPH•Aurinia's Q3 revenue rose 14% year over year, driven by LUPKYNIS sales, while diluted EPS was flat at $0.23. The company raised its 2026 total revenue guidance to $325 million-$330 million and narrowed its net product sales outlook to $310 million-$315 million.
Aurinia reported Q3 product revenue of $79.42 million and net income of $31.70 million. Diluted EPS was $0.23, unchanged year over year. Higher LUPKYNIS sales and increased license, collaboration and royalty revenue contributed to revenue growth.
The company raised its 2026 total revenue guidance to $325 million-$330 million from $315 million-$325 million, and narrowed its net product sales guidance to $310 million-$315 million. Aurinia also began a Phase 4 study combining LUPKYNIS with other therapies for lupus nephritis.
